Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CCR8 | P51685 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22660180 | 0.89 | L3MBTL1 (0.56) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL1717631 | 0.88 | USP30 (0.55) | L3MBTL1ATMS1PR5ALDH1A1CCR8 | |
| SCHEMBL1717630 | 0.88 | USP30 (0.55) | L3MBTL1ATMS1PR5ALDH1A1CCR8 | |
| SCHEMBL14791219 | 0.88 | USP30 (0.55) | L3MBTL1ATMS1PR5ALDH1A1CCR8 | |
| SCHEMBL14791220 | 0.88 | USP30 (0.55) | L3MBTL1ATMS1PR5ALDH1A1CCR8 | |
| SCHEMBL24555862 | 0.88 | USP30 (0.55) | L3MBTL1ATMS1PR5ALDH1A1CCR8 | |
| SCHEMBL6673714 | 0.88 | USP30 (0.55) | L3MBTL1ATMS1PR5ALDH1A1CCR8 | |
| SCHEMBL4862883 | 0.88 | L3MBTL1 (0.57) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL1282973 | 0.87 | S1PR5 (0.53) | S1PR5LTA4H | |
| SCHEMBL21748601 | 0.86 | L3MBTL1 (0.56) | L3MBTL1ATMALDH1A1CCR8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020239077-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| US-9663522-B2 | 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| WO-2012045124-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | BIOTA EUROPE LTD (GB) | 2012-04-12 | — | — | WO | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | L3MBTL1 3411/4885ATM 4553/4885S1PR5 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.